ReviewBiomedicines2021
Current and Emerging Therapies for Metastatic Castration-Resistant Prostate Cancer (mCRPC).
Review in Biomedicines, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Quantitative PSMA PET Biomarkers for Predicting Response toJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Pooled it
- Pooled it
- A phase 2 study of AZD4635 in combination with durvalumab or oleclumab in patients with metastatic castration-resistant prostate cancer.Cancer immunology, immunotherapy : CII · 2024Trial
- Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial.Annals of oncology : official journal of the European Society for Medical Oncology · 2023Trial
- Clinical efficacy of radium-223 in simulating real-world clinical practice: a meta-analysis.Annals of nuclear medicine · 2026Review
- Prevalence of adverse events following T-cell redirecting therapies in patients with metastatic castration-resistant prostate cancer: a pooled analysis.The oncologist · 2026Article
- Predictive value of interim ¹¹C-choline PET/CT for response to radium-223 in metastatic castration-resistant prostate cancer.EJNMMI research · 2026Article
- Breaking barriers in prostate cancer: the mRNA vaccine breakthrough and what comes next.NPJ vaccines · 2026Review
- Impact of androgen receptor pathway inhibitors on cognitive function in older adults treated for metastatic prostate cancer.Communications medicine · 2025Article
- Preclinical Development of GT-14, a Novel Inhibitor of GαThe AAPS journal · 2025Article
- Investigating key genes and molecular mechanisms of prostate cancer and coronary heart disease through transcriptomics and experimental validation.Translational andrology and urology · 2025Article
- Article
- Comparison of Real-World Outcomes between Patients with BRCA1/2-Positive and Homologous Recombination Repair-Negative Metastatic Castration-Sensitive Prostate Cancer.Advances in therapy · 2025Article
- A Bayesian Network Meta-analysis of Systemic Treatments for Metastatic Castration-Resistant Prostate Cancer in First- and Subsequent Lines.Targeted oncology · 2025Article
- (-)-Oleuropein as a Novel Metastatic Castration-Resistant Prostate Cancer Progression and Recurrence Suppressor via Targeting PCSK9-LDLR Axis.Nutrients · 2025Article
- Review
- A PSMA-Targeted Tri-Specific Killer Engager Enhances NK Cell Cytotoxicity against Prostate Cancer.Cancer immunology research · 2025Article
- Article
- Identifying MTHFD1 and LGALS4 as Potential Therapeutic Targets in Prostate Cancer Through Multi-Omics Mendelian Randomization Analysis.Biomedicines · 2025Article
- Bone health management in endocrine-treated patients with prostate cancer: a summary of evidence.BMC urology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metastatic castration-resistant prostate cancer (mCRPC) encompasses a heterogeneous wide range of molecular tumor behavior and a high risk of progression. Early detection and treatment are therefore crucial in these patients. Treatment has improved drastically in recent years and many novel therapeutic agents are currently under investigation. However, due to the rapidly changing therapeutic landscape in mCRPC, it is difficult for clinicians to keep up to date with the latest innovations in this area. In the present narrative review, we discuss the current and emerging therapies for mCRPC as well as the clinical and molecular factors that can help predict which patients are most likely to benefit from these novel agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.